The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Rubin RL

Drug-induced lupus.

Toxicology. 2005;209(2):135-47

Pollak PT

Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations.

The American journal of cardiology. 1999;84(9A):37R-45R

Ohtani Y, Sumi Y, Hisauchi K, Sawada M, Miyake S, Yamashita Y, Mitunaga K, Yoshizawa Y

[Procainamide-induced lupus in a patient with bilateral pleural effusion].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society. 1998;36(6):535-40

Byrd RB, Schanzer B

Pulmonary sequelae in procaine amide induced lupus-like syndrome.

Diseases of the chest. 1969;55(2):170-2

Fakhro AM, Ritchie RF, Lown B

Lupus-like syndrome induced by procainamide.

The American journal of cardiology. 1967;20(3):367-73

Smith PR, Nacht RI

Drug-induced lupus pleuritis mimicking pleural space infection.

Chest. 1992;101(1):268-9